Next-generation recombinant HA antigen for faster, more accurate IBV detection.
A precisely engineered recombinant HA antigen designed to deliver consistent performance, stronger diagnostic accuracy, and reliable IBV strain identification.
What is IBV and how is it detected?
Infectious Bronchitis Virus (IBV) is a highly contagious disease affecting poultry.
Fast and reliable detection is critical to controlling outbreaks and reducing economic loss.
The haemagglutination (HA) assay is an established method used in IBV diagnostics and strain identification, relying on the virus’s ability to bind red blood cells.
However, the accuracy of this test is highly dependent on the antigen used; making antigen quality a key factor in achieving consistent, reliable diagnostic performance.
Traditional antigen production is complex, slow, and difficult to scale
Traditional virus-derived IBV antigens can create variability, long lead times, and inconsistent assay performance. Pure HA Diagnostics provides a stable, scalable recombinant alternative designed to produce stronger, more reliable diagnostic signals.
This helps diagnostic teams:
Improve assay accuracy
Support earlier outbreak detection
Access a dependable antigen supply
A better alternative: recombinant HA antigen
PureHA Diagnostics has developed a recombinant HA antigen specifically designed for IBV, providing a direct replacement for traditional virus-derived antigens used in HA assays.
By removing the need for egg-based production, our approach delivers a more controlled, scalable, and reliable solution for modern diagnostics.
Accurate detection
Engineered to deliver strong, reliable hemagglutination performance for dependable IBV testing.
Consistent results
Manufactured without live virus to reduce batch-to-batch variability and improve reproducibility.
Scalable supply
Recombinant production supports faster, more efficient manufacturing for commercial and laboratory demand.
Be first to access Pure HA Diagnostics
Join the waiting list to access our next-generation HA antigen, register your interest in pilot testing, or explore early-stage collaboration opportunities.
PureHA Diagnostics is developing a recombinant HA antigen to advance IBV diagnostics with greater consistency, precision, and supply reliability than traditional approaches.
Key Features
Precision-engineered HA activity
High consistency and reproducibility
No reliance on live virus or egg-based production
Scalable, efficient manufacturing
Designed as a direct replacement for traditional HA antigens
Who is PureHA Diagnostics for?
PureHA Diagnostics is designed for organisations and experts working at the forefront of poultry health and IBV detection. From diagnostic developers and laboratory scientists to biotech companies, government agencies, and poultry producers, our recombinant HA antigen supports those who require consistent, high-performance tools to improve assay accuracy, strengthen surveillance, and enable better decision-making.
Veterinary diagnostic developers
Animal health biotech companies
Laboratory scientists and virologists
Government animal health agencies
Academic avian disease researchers
Poultry producers and integrators
Designed for reliability. Built for scale.
To enquire about early access or if you have any questions, we would love to hear from you.
